Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. - Wikidata - awgldk - TriplyDB

Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.

Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.

http://www.wikidata.org/entity/Q37031917

about

Tumor refractoriness to anti-VEGF therapy Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial Broad targeting of angiogenesis for cancer prevention and therapy DLL4 promotes continuous adult intestinal lacteal regeneration and dietary fat transport.Tongxinluo mitigates atherogenesis by regulating angiogenic factors and inhibiting vasa vasorum neovascularization in apolipoprotein E-deficient mice High-precision, non-invasive anti-microvascular approach via concurrent ultrasound and laser irradiation.Designing a broad-spectrum integrative approach for cancer prevention and treatment.Factors regulating capillary remodeling in a reversible model of inflammatory corneal angiogenesis The biomechanical properties of an epithelial tissue determine the location of its vasculature Correlative Imaging of the Murine Hind Limb Vasculature and Muscle Tissue by MicroCT and Light Microscopy.VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis.Histamine H4 receptor as a new therapeutic target for choroidal neovascularization in age-related macular degeneration Modulation of age-related insulin sensitivity by VEGF-dependent vascular plasticity in adipose tissues Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.Curcumin inhibits angiogenesis and improves defective hematopoiesis induced by tumor-derived VEGF in tumor model through modulating VEGF-VEGFR2 signaling pathway.VEGF-B promotes cancer metastasis through a VEGF-A-independent mechanism and serves as a marker of poor prognosis for cancer patients A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism.Pericyte-fibroblast transition promotes tumor growth and metastasis.Antiangiogenic cancer treatment: The great discovery and greater complexity (Review).Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy PPARG is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs.Future options of anti-angiogenic cancer therapy.Role of plasma membrane caveolae/lipid rafts in VEGF-induced redox signaling in human leukemia cells.Thyroid disease in pregnancy: new insights in diagnosis and clinical management.Evaluation of epigenetic inactivation of vascular endothelial growth factor receptors in head and neck squamous cell carcinoma.Inhibition of hypoxia-inducible factor via upregulation of von Hippel-Lindau protein induces "angiogenic switch off" in a hepatoma mouse model.Intestinal lymphatic vasculature: structure, mechanisms and functions.High-resolution 3D analysis of mouse small-intestinal stroma.von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans.Ablation of endothelial VEGFR1 improves metabolic dysfunction by inducing adipose tissue browning.Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel.Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production.Organotypic vasculature: From descriptive heterogeneity to functional pathophysiology.Dual roles of endothelial FGF-2-FGFR1-PDGF-BB and perivascular FGF-2-FGFR2-PDGFRβ signaling pathways in tumor vascular remodeling.Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy.Changes in cross-sectional area of pulmonary vessels on chest computed tomography after chemotherapy in patients with advanced non-squamous non-small-cell lung cancer.TNFR1 mediates TNF-α-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling.

P2860

Q26747678-3C41523D-CE28-4100-84EE-22FB1BF63C2E Q26824777-2AC2155D-C810-44D2-AC9A-95717F5F3E14 Q27002903-A99F0EB9-18E7-4C8B-A884-1ABDC9DFC937 Q27331693-3279EDAF-193E-429E-93D8-4E18679B6116 Q28383906-96C1B5FD-E556-4C6F-81C9-86CEEA13708B Q30365660-664F1D52-3F18-4FAA-BCF6-A92F12DD39BF Q30736359-714B2A5E-81F4-4E2C-AF0D-501A24920EFB Q30804219-B761E867-0530-4A64-91C6-0E17D474CDA7 Q30833091-1A0FA113-6D3F-4CEB-8014-711896B38B87 Q30837730-53447B53-35B1-4E36-90D8-831EEDF135FA Q33748993-11AC37B2-AFB2-49D3-AD07-0F53BF485B57 Q34025192-23242EBD-1E81-4933-AED2-496E6A1AEE17 Q34383803-8E2DF9AD-4000-4481-82E9-52131B4CC534 Q34468729-E71E2F7F-4F0B-4037-9F4D-4C701322360C Q34672128-CEDC33D4-00A9-41CE-9203-58118D85ACF7 Q35698934-AD070941-0785-4FF5-B9D9-6A0BF33E9CC7 Q36216092-E1E3B463-9BE9-4348-89A5-A203C56E369B Q36821570-3281DCA0-837A-4F06-8AB3-E137F75FEA2C Q37260920-5E609FE3-5872-4E80-AB8D-9588E0B31840 Q37281490-53A39B48-251B-4A7B-9CD8-02F9791FEA86 Q37337814-6B17C388-C874-4316-8C03-B0EC10594E38 Q37524215-7A2DCBB0-DDA9-4B63-8676-64CC80515750 Q37734001-2274ED5C-BD4F-4486-A297-FD6449B153DE Q38232368-D8EC63B9-DCED-47AC-B8BB-331C3A846832 Q38438425-B32F7539-43F2-456B-BEAA-E305F1026FAE Q38540266-4D097200-8824-4345-BDC2-2C01D6003668 Q38641495-695FF002-84C9-4ACF-9B74-51FF1A3045EA Q38697010-9D03F3AE-462B-4EF5-AEB3-C148C5A97AD4 Q38845185-1F2C0BCB-A527-47BD-963B-15E1800F239A Q39401415-18AF7503-0CE6-4A8F-B844-56B63A9B8250 Q40563361-6DCBECBF-0E51-4EDB-B4EA-F7F985B450A1 Q40671371-84C4EA1C-1571-47A7-B3AE-D5F1F1969A98 Q47203673-043F7DCB-10C7-4E81-904E-627A50B3E7A0 Q47418219-5FF94F2B-1813-4F80-A698-C374538BC3FC Q47701879-11112B51-D105-4112-95A9-0A6221DAD852 Q47836465-BA027783-3700-49DD-8E87-E8C08D4212C2 Q49384248-3944101E-CC1A-42C5-AB2B-6055DDDDEDCA Q52682124-3E7E15BA-1671-44AE-82FD-3F12BE7B9B38 Q52877451-97ECEE66-7069-4809-B636-E5A178A2C121 Q54321573-73F78837-F6D9-48AF-9AAF-43B9F773315C

P2860

Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.

http://www.wikidata.org/entity/Q37031917

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.

@en

Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.

@nl

type

label

Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.

@en

Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.

@nl

prefLabel

Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.

@en

Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.

@nl

P1433

Q37031917-86FB9EEB-A18F-464B-8656-C99CC51EA541

P1476

Q37031917-F76CFDC9-5B47-40D1-9B84-B4C9D305A138

P2093

Q37031917-235536CB-4AB3-42B6-877B-B3737E2E022C

Q37031917-24D6DEF2-EFD6-4634-9D97-25A099D3A781

Q37031917-30510A2F-389B-42DB-AEF7-D1B0D19972AE

Q37031917-A2F932A9-E0E1-4A1F-987B-151962BA5273

Q37031917-B9ECA7BD-748D-4CF7-9354-764F8C0B61B2

Q37031917-C503F157-F5AD-43D2-A747-DEADEC3D696B

Q37031917-C622876A-BA47-42B7-B9C6-6CBCC2440968

Q37031917-E1E4F12D-0503-48CC-ADB2-A98BA61FF33C

Q37031917-F0C0E033-CEFB-43FB-8160-90D4C5AE2ADB

P2860

Q37031917-16F8146C-2221-4B2E-900A-BEA90FC86A7B

Q37031917-192781EF-5121-4582-8F56-3F95F75BE2CE

Q37031917-1B31C45B-F0FA-44F4-9C04-2E7E398F84AC

Q37031917-1F237892-0B9A-45EC-B856-A34A53F78E44

Q37031917-25845721-874D-412B-B07D-8CF0BD7A9ED9

Q37031917-2A304CDC-39B5-4A87-AE93-07EE7F644585

Q37031917-2EAD63A3-7803-4B75-993B-DF8F2F04A4FA

Q37031917-2EFB7A0E-12F4-4C84-B341-3945F9EE15FF

Q37031917-4146DE21-D901-4F0D-9A52-AB7105F3D873

Q37031917-425988DD-A956-44FA-9887-31618AD8671B

P304

Q37031917-93622CDF-356E-43B3-BE7F-55D09F29BADD

P31

Q37031917-65B5477A-7F42-4AE7-930C-E0EA5CB39259

P356

Q37031917-E75D9128-0838-442F-88D7-7782189FDCD7

P407

Q37031917-9D0166E5-FF5C-446C-AF3C-C53004A45004

P433

Q37031917-8926A98E-D2D8-4660-95CD-DDDD7B1BB6D8

P478

Q37031917-253D452B-C329-4361-8982-AC391DDE2F14

P50

Q37031917-A19FF2D8-A9E3-4EFA-80AF-43C8727B4806

P577

Q37031917-C049CD1F-73BC-4063-83D4-35FF05947194

P5875

Q37031917-A9313425-07EE-4219-BC9B-63A4DEACF05E

P698

Q37031917-99BFBA76-64C4-41BB-9308-18E3A5785964

P932

Q37031917-43D4D505-322D-417B-8506-F1983FFF6328

P356

PNAS.1301331110

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues

@en

P2093

Baocun Sun

http://www.w3.org/2001/XMLSchema#string

Eric Wahlberg

http://www.w3.org/2001/XMLSchema#string

Hideki Iwamoto

http://www.w3.org/2001/XMLSchema#string

Hong Ji

http://www.w3.org/2001/XMLSchema#string

Xiaojuan Yang

http://www.w3.org/2001/XMLSchema#string

Yihai Cao

http://www.w3.org/2001/XMLSchema#string

Yin Zhang

http://www.w3.org/2001/XMLSchema#string

Yunlong Yang

http://www.w3.org/2001/XMLSchema#string

Ziquan Cao

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor angiogenesis: therapeutic implications

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

The biology of VEGF and its receptors

Angiogenesis in cancer and other diseases

Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Vascular endothelial growth factor is a secreted angiogenic mitogen

A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models

Properties of Two VEGF Receptors, Flt-1 and KDR, in Signal Transductiona

P304

12018-12023

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1301331110

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

244482676

http://www.w3.org/2001/XMLSchema#string

P698

23818623

http://www.w3.org/2001/XMLSchema#string

P932

3718173

http://www.w3.org/2001/XMLSchema#string